Patents Assigned to Can-Fite Biopharma Ltd.
-
Publication number: 20120065155Abstract: The present disclosure provides the use of an A3R agonist, such as IB-MECA, for reducing in a subject, preferably, human subject, intra ocular pressure (IOP). Similarly, the invention provides a pharmaceutical composition and a method for reducing IOP in a subject making use of the A3R agonist.Type: ApplicationFiled: May 16, 2010Publication date: March 15, 2012Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina Fishman, Mordechai Farbstein
-
Publication number: 20110144156Abstract: Provided are 2,4-disubstituted quinoline derivatives that are A3 adenosine receptor modulators (A3RM), for use in the treatment of a condition which is treatable by adenosine, an A3 adenosine receptor (A3AR) agonist, or an A3 adenosine receptor antagonist. The 2,4-disubstituted quinoline derivatives can be used in the treatment of a condition treatable by an adenosine or an A3AR agonist, by enhancing activity of a protein (by binding of said 2,4-disubstituted quinoline derivative to the A3AR). Some conditions treatable by the 2,4-disubstituted quinoline derivative when used for enhancing activity include, malignancy, an immuno-compromised affliction, high intraocular pressure, or a condition associated with high intraocular pressure.Type: ApplicationFiled: August 12, 2009Publication date: June 16, 2011Applicants: UNIVERSITEIT LEIDEN, CAN-FITE BIOPHARMA LTD.Inventors: Adriaan P. Ijzerman, Aniko Goblyos, Johannes Brussee
-
Patent number: 7825102Abstract: The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A3 adenosine receptor (A3AR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is manifested by one or more ophthalmologic clinical symptoms selected from foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, degraded vision and excessive tearing. A preferred A3RAg in accordance with the invention is N6-(3-iodobenzyl)-adenosine-5?-N-methyluronamide (IB-MECA).Type: GrantFiled: November 28, 2006Date of Patent: November 2, 2010Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Tatiana Reitblat, Ilan Cohn
-
Publication number: 20100256084Abstract: Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A3AR agonist.Type: ApplicationFiled: June 21, 2010Publication date: October 7, 2010Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina Fishman, Sara Bar-Yehuda, Lea Madi
-
Publication number: 20100249053Abstract: The present application provides methods and compositions for inducing hepatocyte proliferation and liver regeneration, the latter being mainly dependent on hepatocyte proliferation even if all the other cell types divide to reconstitute the organ specific-lobular-architecture. The methods and compositions provided herein make use of an A3AR agonist. A preferred A3AR agonist disclosed herein is Cl-IB-MECA.Type: ApplicationFiled: October 22, 2008Publication date: September 30, 2010Applicant: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Shira Cohen
-
Publication number: 20100222369Abstract: The present invention provides a method for treating dry eye condition in an individual comprising administrating to said individual an amount of A3 adenosine receptor (A3AR) agonist, the amount being effective to ameliorate symptoms of dry eye in the individual. In accordance with one embodiment, the dry eye condition is manifested by one or more opthalmologic clinical symptoms selected from foreign body sensation, burning, itching, irritation, redness, eye pain, blurred vision, degraded vision and excessive tearing. A preferred A3RAg in accordance with the invention is N6-(3-iodobenzyl)-adenosine-5?-N-methyluronamide (IB-MECA).Type: ApplicationFiled: May 6, 2010Publication date: September 2, 2010Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina FISHMAN, Tatiana REITBLAT, Ilan COHN
-
Patent number: 7589075Abstract: The present invention concerns the use of an active ingredient selected from the group consisting of agonists of the adenosine receptor system, for inhibiting viral replication in cells. In particular, the invention provides a composition and method for inhibiting viral replication in cells, the method comprising presenting to the cells an effective amount of the active ingredient. According to one embodiment, the adenosine agonist is an A3 receptor agonist (A3RAg). The invention is particularly useful, for although not limited to, inhibiting the replication of HIV virus in human cells.Type: GrantFiled: January 13, 2002Date of Patent: September 15, 2009Assignee: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Kamel Khalili
-
Patent number: 7465715Abstract: Individuals suffering from multiple sclerosis may be treated by administration of an A3 adenosine receptor agonist (A3RAg), such as APNEA, AB-MECA, IB-MECA or Cl-IB-MECA. The A3RAg is preferably administered orally with a pharmaceutically acceptable carrier.Type: GrantFiled: December 23, 2004Date of Patent: December 16, 2008Assignee: Can-Fite Biopharma, Ltd.Inventors: Pnina Fishman, Sara Bar Yehuda, Lea Madi
-
Publication number: 20080056992Abstract: Inflammatory state in a subject is assayed by determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBC), e.g. circulating WBCs, from the subject. A high level of expression of A3AR is indicative of an inflammatory state in the subject. This assay can be used for determining the severity of inflammation in a subject and monitoring the efficacy of anti-inflammatory treatment. Also, the level of expression may be used for selecting patients to receive an anti-inflammatory treatment that comprises an A3AR agonist.Type: ApplicationFiled: November 30, 2005Publication date: March 6, 2008Applicant: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Sara Bar-Yehuda, Lea Madi
-
Publication number: 20080051365Abstract: The present invention concerns the therapeutic treatment of inflammatory conditions by a combined administration of methotrexate and an agonist of the A3 adenosine receptor. Provided are methods of therapeutic treatment comprising such a combined administration, pharmaceutical compositions useful in such methods comprising either an and use if either an agonist of the A3 adenosine receptor or methotrexate, as well as used of any of these active agents for preparing such a pharmaceutical composition.Type: ApplicationFiled: November 30, 2005Publication date: February 28, 2008Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina Fishman, Sara Bar-Yehuda
-
Patent number: 7189706Abstract: The present invention concerns novel C2,5?-disubstituted and N6,C2,5?-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.Type: GrantFiled: September 3, 2003Date of Patent: March 13, 2007Assignees: Universiteit Leiden, Can-Fite Biopharma Ltd.Inventors: Erica Van Tilburg, Ad Ijzerman
-
Patent number: 7141553Abstract: The present invention concerns a method for the treatment of inflammatory arthritis, and in particular rheumatoid arthritis, by administering to the subject specific low dosages of N6-(3-iodobenzyl)-adenosine 5?-N-methyl-uronamide (IB-MECA) and 2-chloro-N6-(3-iodobenzyl)-adenosine-5?-N-methyl-uronamide (CL-IB-MECA).Type: GrantFiled: November 19, 2003Date of Patent: November 28, 2006Assignee: Can-Fite Biopharma Ltd. IsraelInventor: Pnina Fishman
-
Publication number: 20060241069Abstract: A short interfering RNA (siRNA) duplex that includes complementary sense and anti-sense sequences corresponding to at least part of the A3 adenosine receptor (A3AR) mRNA sequence, a double-stranded RNA (dsRNA) construct that can be converted within a cell into a siRNA duplex and a transcript system that can induce transcription within cells of either a siRNA duplex or a dsRNA construct Also disclosed are a method and a pharmaceutical composition for treating a hyperproliferative disease.Type: ApplicationFiled: February 24, 2005Publication date: October 26, 2006Applicant: Can-Fite Biopharma Ltd.Inventors: Pnina Fishman, Lea Madi, Sara Bar Yehuda
-
Patent number: 7112574Abstract: Novel C2,8-disubstituted adenosine derivatives disclosed herein have been found to be potent adenosine receptor agonists, in particular for the A2A receptor. The said compounds have biological activity against conditions such as hypertension, ischemic heart disease, ischemic brain disease, psychosis and wound healing. Further, the invention also discloses a process for the preparation of such compounds and pharmaceutical compositions comprising them.Type: GrantFiled: March 3, 2002Date of Patent: September 26, 2006Assignees: Universiteit Leiden, Can-Fite Biopharma Ltd.Inventors: Erica Van Tilburg, Ad Ijzerman
-
Patent number: 7084127Abstract: The present invention concerns novel C2,5?-disubstituted and N6?,C2,5?-trisubstituted adenosine derivatives and their different uses. These adenosine derivatives were found to be potent adenosine receptor agonists and thus are of a therapeutic value in the treatment and prophylaxis of diseases and disorders affected by adenosine receptor agonists.Type: GrantFiled: March 3, 2002Date of Patent: August 1, 2006Assignees: Universiteit Leiden, Can-Fite Biopharma Ltd.Inventors: Erica Van Tilburg, Ad Ijzerman
-
Publication number: 20060142237Abstract: Use of an A3 adenosine receptor agonist in the preparation of a pharmaceutical composition for the treatment of an individual suffering from multiple sclerosis. The composition is preferably orally administered. Also disclosed is a pharmaceutical composition for the treatment of multiple sclerosis that comprises an effective amount of an A3 adenosine receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: December 23, 2004Publication date: June 29, 2006Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina Fishman, Sara Bar Yehuda, Lea Madi
-
Patent number: 7064112Abstract: Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell growth and proliferation.Type: GrantFiled: September 8, 2000Date of Patent: June 20, 2006Assignee: Can-Fite Biopharma Ltd.Inventor: Pina Fishman
-
Publication number: 20060084626Abstract: Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopenia, particularly drug-induced leukopenias; and inhibition of abnormal cell growth and proliferation.Type: ApplicationFiled: November 25, 2005Publication date: April 20, 2006Applicant: Can-Fite Biopharma Ltd.Inventor: Pina Fishman
-
Publication number: 20050277615Abstract: An anti-inflammatory pharmaceutical composition comprising as active ingredient a compound of general formula (I): wherein W represents oxygen or sulfur atoms; R1 represents lower alkyl or lower cycloalkyl; R2 represents halogen, alkenyl, alkynyl or alkylidenhydrazino; R3 represents a lower alkyl, lower cycloalkyl, aryl, (ar)alkyl or anilide, said cycloalkyl, aryl and (ar)alkyl may be substituted with one or more of the groups selected from halogen, hydroxyl, hydroxyalkyl; and a pharmaceutically acceptable additive. The composition may be used to threat diseases such as multiple sclerosis, rheumatoid arthritis and Crohn's disease.Type: ApplicationFiled: May 17, 2004Publication date: December 15, 2005Applicant: CAN-FITE BIOPHARMA LTD.Inventors: Pnina Fishman, Sara Bar Yehuda, Lea Madi
-
Patent number: 6911435Abstract: Adenosine and active agent which interact with the adenosine system are used to treat conditions of weakened, immune system, as an anti-cancer therapy and for improving the therapeutic index of a variety of therapeutic drugs.Type: GrantFiled: July 10, 1998Date of Patent: June 28, 2005Assignee: Can-Fite Biopharma Ltd.Inventors: Ilan Cohn, Pnina Fishman